Metabolic Diseases: Clinical Trials

3,269 trials for Metabolic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2099 completed, 509 unknown, 230 terminated, 170 recruiting. 3269 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43269Completed 2099, Unknown 509, Terminated 230, Recruiting 170, Withdrawn 116, Not yet recruiting 74, Active not recruiting 53, Enrolling by invitation 14, Suspended 4

Follow Metabolic Diseases: new trials by email Literature Review of Metabolic Diseases trials Research Report on Metabolic Diseases

Trials (filtered) newest first · largest first

All 3,269 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessing Trauma-related Links Between Affective and Metabolic Systems
prazosin - Posttraumatic Stress Disorder, Metabolic Syndrome
Phase 4Not yet recruitingVA Office of Research and Development702027-03-012026-10-15
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia
Phase 4Not yet recruitingAmgen3082027-01-312026-09-21
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women
Phase 4Not yet recruitingSahlgrenska University Hospital2162027-01-112026-08-19
Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes
Insulin icodec - Type 2 Diabetes
Phase 4Not yet recruitingXi'an International Medical Center Hospital4622027-01-012026-08-05
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis
Phase 4Not yet recruitingMassachusetts General Hospital1002027-01-012026-11-03
Efficacy of Topical Lidocaine Gel vs. Oral Duloxetine for Painful Diabetic Peripheral Neuropathy
Topical Lidocaine 2% Gel, Duloxetine (60 MG) - Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies
Phase 4Not yet recruitingWah Medical college , POF hospital802026-12-012026-09-02
Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA
iron sulfate - Iron Deficiency Anemia
Phase 4Not yet recruitingLoma Linda University1002026-12-012026-07-10
Pharmacogenetics of Response to Sitagliptin (PRS)
Oral Glucose Tolerance Test - Diabetes
Phase 4Not yet recruitingUniversity of Maryland, Baltimore4002026-12-012026-02-18
Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC)
The intervention with the MCM is Kidney-Heart GDMT initiation and titration for dose optimization (as clinically tolerated), within 4 months of enrollment in the study. - Chronic Kidney Disease, Type II Diabetes
Phase 4Not yet recruitingBaim Institute for Clinical Research5702026-12-012026-09-10
Sucrosomial Vs Intravenous Iron for Preoperative Anemia
Treatment with oral sucrosomial iron, Treatment with intravenous iron - Anemia, Iron Deficiency Anemia
Phase 4WithdrawnUniversity of Rochester2026-12-012026-10-06
Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Sotagliflozin, Empagliflozin (oral), Metformin - Type 2 Diabetes Mellitus (DM)
Phase 4Not yet recruitingAllied Hospital Faisalabad1402026-12-012026-11-16
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency
Ferric derisomaltose, Placebo (normal saline) - Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Phase 4Not yet recruitingDuke University3002026-11-012026-10-15
Metabolic Surgery for Atrial Fibrillation Elimination
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment - Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Phase 4Not yet recruitingAli Aminian1002026-11-012026-04-17
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA
Phase 4Not yet recruitingRehman Medical Institute - RMI1782026-11-012026-11-05
Iron Repletion in Cystic Fibrosis
IV Repletion, PO Repletion - Cystic Fibrosis, Iron Deficiencies
Phase 4Not yet recruitingUniversity of Michigan1002026-11-012026-10-29
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
inclisiran, SOC - Acute Coronary Syndrome
Phase 4Not yet recruitingNovartis Pharmaceuticals3002026-10-312026-10-30
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab) - MAFLD in Prediabetes and Diabetes
Phase 4Not yet recruitingSherihan AboElyazed Mohamed Khalil662026-10-012026-10-23
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Orforglipron - Diabete Type 2, Pharmacogenomic Drug Interaction
Phase 4Not yet recruitingMassachusetts General Hospital1002026-10-012026-08-31
PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)
Eroxon®, tadalafil - Type 2 Diabetes, Type 2 Diabetes (T2DM)
Phase 4SuspendedUniversity of Miami302026-10-012026-09-28

Showing 20 of 3269. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (1186)  ·  Diabetes Mellitus (737)  ·  Insulin Resistance (285)  ·  Diabetes Mellitus, Type 1 (191)  ·  Osteoporosis (166)  ·  Hypertension (165)  ·  Hypercholesterolemia (148)  ·  Obesity (141)  ·  Metabolic Syndrome (139)  ·  Dyslipidemias (130)  ·  Anemia, Iron-Deficiency (102)  ·  Coronary Artery Disease (100)  ·  Cardiovascular Diseases (92)  ·  Hyperglycemia (81)  ·  Renal Insufficiency, Chronic (79)

Broader conditions

Nutritional and Metabolic Diseases (3268)  ·  Glucose Metabolism Disorders (2163)  ·  Endocrine System Diseases (1943)  ·  Diabetes Mellitus (1146)  ·  Pathological Conditions, Signs and Symptoms (572)  ·  Cardiovascular Diseases (499)  ·  Vascular Diseases (438)  ·  Lipid Metabolism Disorders (404)  ·  Hyperinsulinism (399)  ·  Urogenital Diseases (340)  ·  Musculoskeletal Diseases (321)  ·  Pathologic Processes (314)  ·  Signs and Symptoms (289)  ·  Bone Diseases (276)

Interventions

Metformin (294)  ·  Insulin Glargine (216)  ·  Sitagliptin Phosphate (120)  ·  dapagliflozin (117)  ·  Insulin (108)  ·  Pioglitazone (100)  ·  Insulin Aspart (93)  ·  Atorvastatin (91)  ·  empagliflozin (82)  ·  Liraglutide (71)  ·  glimepiride (65)  ·  Exenatide (61)  ·  Ezetimibe (60)  ·  Rosuvastatin Calcium (58)  ·  Insulin Lispro (57)

Sponsors

Sanofi (115)  ·  Novo Nordisk A/S (85)  ·  Novartis Pharmaceuticals (51)  ·  Eli Lilly and Company (50)  ·  AstraZeneca (41)  ·  GlaxoSmithKline (30)  ·  Genzyme, a Sanofi Company (27)  ·  Novartis (26)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (26)  ·  Emory University (25)  ·  Massachusetts General Hospital (23)  ·  Organon and Co (23)  ·  Seoul National University Bundang Hospital (23)  ·  Yonsei University (23)  ·  Seoul National University Hospital (22)

Countries

United States (932)  ·  China (273)  ·  South Korea (218)  ·  Germany (154)  ·  Canada (153)  ·  United Kingdom (148)  ·  Italy (143)  ·  Spain (130)  ·  Denmark (118)  ·  Netherlands (103)  ·  France (102)  ·  Japan (89)  ·  Mexico (87)  ·  Brazil (82)  ·  India (77)

Top investigators

Guillermo Umpierrez, MD (12)

Results publications

PMID 33166419, PMID 32501595, PMID 37435938, PMID 39963952, PMID 34231877, PMID 38018702, PMID 33210751, PMID 34693515, PMID 35224730, PMID 37467180, PMID 37526194, PMID 38682786, PMID 38770818, PMID 40576086, PMID 25765670, PMID 32588430, PMID 32803882, PMID 39641307, PMID 40875095, PMID 11138687, PMID 16018754, PMID 17513708, PMID 19156705, PMID 19366972, PMID 19454394, PMID 20536957, PMID 20923490, PMID 21228246, PMID 21297494, PMID 22002075, PMID 22773702, PMID 22775317, PMID 23435159, PMID 24445038, PMID 30779243, PMID 31865758, PMID 33107592, PMID 33293204, PMID 33813753, PMID 35322793, PMID 35478046, PMID 36088628, PMID 36262060, PMID 37853560, PMID 38189593, PMID 38323855, PMID 38700045, PMID 38979716, PMID 39443013, PMID 39527056

NIH funding

2015 (27), 2014 (14), 2016 (14), 2008 (13), 2019 (12), 2018 (9), 2005 (8), 2025 (7), 2009 (6), 2023 (6), 2017 (5), U54RR014616 (3), R01AR071263 (2), R01DK077166 (2), R01DK107680 (2)